Plain-English translation of NCT06823089 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This early feasibility study is testing a new hip implant called the ReNew Hip Implant, which is designed to repair damaged cartilage in the hip joint. Unlike traditional hip replacement surgery that removes and replaces the entire joint, this implant is a bioabsorbable device that fills in cartilage defects while preserving your healthy bone. The implant is designed to feel and function like natural cartilage, giving younger and more active patients an alternative to full hip replacement.
Currently, younger patients with hip arthritis who have tried physical therapy, medications, and injections without relief face a difficult choice: either live with pain or have their entire hip joint replaced. Full hip replacement requires significant lifestyle changes and will likely need to be replaced again during their lifetime. This new treatment offers a less invasive option that preserves bone and gives patients a chance to delay or avoid full joint replacement.
You likely qualify if…
You likely don't qualify if…
You will undergo surgery to have the ReNew Hip Implant placed into the damaged area of your hip joint. After surgery, you will attend follow-up appointments with your doctor to monitor how well the implant is working and how your hip is healing. You will be asked to participate in assessments and evaluations for 5 years after your surgery to help researchers understand whether the implant successfully repairs the cartilage damage and allows you to return to your normal activities.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
United States
Sponsor
Cytex Therapeutics, Inc.
Collaborators
MCRA
Enrollment target
~15 participants
Started
November 2025
Primary completion
October 2031
Age range
14 Years – 64 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Brad Estes, PhD
Cytex Therapeutics, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.